← Back to Search

Alinity m HR HPV for Human Papillomavirus

N/A
Waitlist Available
Research Sponsored by Abbott Molecular
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women is eligible if she meets the following:
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights

Study Summary

This trial will be testing two different ways of collecting cervical cancer screening specimens in order to determine which is more effective in detecting disease.

Eligible Conditions
  • Human Papillomavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Women can participate if they meet these requirements:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Progression greater than or equal to (cervical intraepithelial neoplasia) CIN3
Secondary outcome measures
Disease progression greater than or equal to cervical intraepithelial neoplasia (CIN2)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Alinity m HR HPVExperimental Treatment1 Intervention
The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes [(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)].
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alinity m HR HPV
2021
N/A
~14940

Who is running the clinical trial?

Abbott MolecularLead Sponsor
2 Previous Clinical Trials
264 Total Patients Enrolled

Media Library

Alinity m HR HPV Clinical Trial Eligibility Overview. Trial Name: NCT04746872 — N/A
Human Papillomavirus Research Study Groups: Alinity m HR HPV
Human Papillomavirus Clinical Trial 2023: Alinity m HR HPV Highlights & Side Effects. Trial Name: NCT04746872 — N/A
Alinity m HR HPV 2023 Treatment Timeline for Medical Study. Trial Name: NCT04746872 — N/A
Human Papillomavirus Patient Testimony for trial: Trial Name: NCT04746872 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How extensive is the geographical coverage of this research endeavor?

"This investigation is enrolling patients from Physicians' Research Options in Lakewood, Colorado; Rex Garn Mabey in Las Vegas, Nevada; and Medical Research Center of Memphis, LLC in Memphis, Tennessee. Additionally there are 58 additional medical centres involved."

Answered by AI

Are there any ongoing opportunities for individuals to participate in this research?

"The posted information on clinicaltrials.gov points to this trial being inactive, having been initially advertised in February 2021 and last updated November 2022. While no longer recruiting participants, there are 367 other studies actively seeking enrollees at present."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
Florida
Texas
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
David I Lubetkin, MD, LLC
Health Awareness, Inc.
Unified Women's Clinical Research -Raleigh
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I would like to help the medical community find a cure for cervicales cancer.
PatientReceived no prior treatments
My best friend died of ovarian cancer. I'd like to help process research in women's health.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Health Awareness, Inc.: < 48 hours
Average response time
  • < 2 Days
~3658 spots leftby Mar 2025